HER2/neu gene determination in women screened for breast carcinoma: How screening programs reduce the skyrocketing cost of targeted therapy

Matteo Brunelli, Erminia Manfrin, Emilio Bria, Francesco Massari, Giampaolo Tortora, Eleonora Brunello, Luisa Carbognin, Alessia Nottegar, Jenny Furlanetto, Annamaria Molino, Elena Fiorio, Marco Chilosi, Bharat Jasani, Marco Vergine, Lisa Marcolini, Dea Filippini, Aldo Scarpa, Guido Martignoni, Franco Bonetti

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Few data on Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast carcinomas have been reported for screen-detected breast carcinoma. Assessing the impact of a targeted intervention with anti-HER2 inhibitors on costs is required in order to plan for better strategies in screening programs. A total of 54,472 women were screened and 323 cases were found to be invasive cancer. We performed immunophenotypical-fluorescent in situ hybridization (FISH) analysis. Among 153 evaluable breast carcinomas, tumours displayed a 3+ scoring status 3+ in 16 (10%), 2+ in 12 (8%), 1+ in 29 (19%) and 0 in 96 (63%) of cases, respectively. All 3+ HER2+ cases and 2/12 2+ (17%) cases exhibited HER2/neu gene amplification, the remaining cases did not. In contrast to the higher incidence reported at the population level, 20-30% HER2-positive cases for metastatic carcinomas, and only 11% of the screen-detected breast carcinomas displayed HER2/neu gene amplification. Breast cancer detection by screening programs hijacks the skyrocketing cost of the use of targeted therapy in HER2-positive carcinoma.

Original languageEnglish
Pages (from-to)3705-3710
Number of pages6
JournalAnticancer Research
Volume33
Issue number9
Publication statusPublished - Sep 2013
Externally publishedYes

Fingerprint

erbB-2 Genes
Breast Neoplasms
Costs and Cost Analysis
Gene Amplification
Therapeutics
Carcinoma
human ERBB2 protein
Fluorescence In Situ Hybridization
Early Detection of Cancer
Incidence

Keywords

  • Cost-effectiveness
  • Gene amplification
  • HER2
  • Screen-detected breast carcinoma
  • Screening
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Brunelli, M., Manfrin, E., Bria, E., Massari, F., Tortora, G., Brunello, E., ... Bonetti, F. (2013). HER2/neu gene determination in women screened for breast carcinoma: How screening programs reduce the skyrocketing cost of targeted therapy. Anticancer Research, 33(9), 3705-3710.

HER2/neu gene determination in women screened for breast carcinoma : How screening programs reduce the skyrocketing cost of targeted therapy. / Brunelli, Matteo; Manfrin, Erminia; Bria, Emilio; Massari, Francesco; Tortora, Giampaolo; Brunello, Eleonora; Carbognin, Luisa; Nottegar, Alessia; Furlanetto, Jenny; Molino, Annamaria; Fiorio, Elena; Chilosi, Marco; Jasani, Bharat; Vergine, Marco; Marcolini, Lisa; Filippini, Dea; Scarpa, Aldo; Martignoni, Guido; Bonetti, Franco.

In: Anticancer Research, Vol. 33, No. 9, 09.2013, p. 3705-3710.

Research output: Contribution to journalArticle

Brunelli, M, Manfrin, E, Bria, E, Massari, F, Tortora, G, Brunello, E, Carbognin, L, Nottegar, A, Furlanetto, J, Molino, A, Fiorio, E, Chilosi, M, Jasani, B, Vergine, M, Marcolini, L, Filippini, D, Scarpa, A, Martignoni, G & Bonetti, F 2013, 'HER2/neu gene determination in women screened for breast carcinoma: How screening programs reduce the skyrocketing cost of targeted therapy', Anticancer Research, vol. 33, no. 9, pp. 3705-3710.
Brunelli, Matteo ; Manfrin, Erminia ; Bria, Emilio ; Massari, Francesco ; Tortora, Giampaolo ; Brunello, Eleonora ; Carbognin, Luisa ; Nottegar, Alessia ; Furlanetto, Jenny ; Molino, Annamaria ; Fiorio, Elena ; Chilosi, Marco ; Jasani, Bharat ; Vergine, Marco ; Marcolini, Lisa ; Filippini, Dea ; Scarpa, Aldo ; Martignoni, Guido ; Bonetti, Franco. / HER2/neu gene determination in women screened for breast carcinoma : How screening programs reduce the skyrocketing cost of targeted therapy. In: Anticancer Research. 2013 ; Vol. 33, No. 9. pp. 3705-3710.
@article{3eea3525ce554643b455945032261072,
title = "HER2/neu gene determination in women screened for breast carcinoma: How screening programs reduce the skyrocketing cost of targeted therapy",
abstract = "Few data on Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast carcinomas have been reported for screen-detected breast carcinoma. Assessing the impact of a targeted intervention with anti-HER2 inhibitors on costs is required in order to plan for better strategies in screening programs. A total of 54,472 women were screened and 323 cases were found to be invasive cancer. We performed immunophenotypical-fluorescent in situ hybridization (FISH) analysis. Among 153 evaluable breast carcinomas, tumours displayed a 3+ scoring status 3+ in 16 (10{\%}), 2+ in 12 (8{\%}), 1+ in 29 (19{\%}) and 0 in 96 (63{\%}) of cases, respectively. All 3+ HER2+ cases and 2/12 2+ (17{\%}) cases exhibited HER2/neu gene amplification, the remaining cases did not. In contrast to the higher incidence reported at the population level, 20-30{\%} HER2-positive cases for metastatic carcinomas, and only 11{\%} of the screen-detected breast carcinomas displayed HER2/neu gene amplification. Breast cancer detection by screening programs hijacks the skyrocketing cost of the use of targeted therapy in HER2-positive carcinoma.",
keywords = "Cost-effectiveness, Gene amplification, HER2, Screen-detected breast carcinoma, Screening, Targeted therapy",
author = "Matteo Brunelli and Erminia Manfrin and Emilio Bria and Francesco Massari and Giampaolo Tortora and Eleonora Brunello and Luisa Carbognin and Alessia Nottegar and Jenny Furlanetto and Annamaria Molino and Elena Fiorio and Marco Chilosi and Bharat Jasani and Marco Vergine and Lisa Marcolini and Dea Filippini and Aldo Scarpa and Guido Martignoni and Franco Bonetti",
year = "2013",
month = "9",
language = "English",
volume = "33",
pages = "3705--3710",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "9",

}

TY - JOUR

T1 - HER2/neu gene determination in women screened for breast carcinoma

T2 - How screening programs reduce the skyrocketing cost of targeted therapy

AU - Brunelli, Matteo

AU - Manfrin, Erminia

AU - Bria, Emilio

AU - Massari, Francesco

AU - Tortora, Giampaolo

AU - Brunello, Eleonora

AU - Carbognin, Luisa

AU - Nottegar, Alessia

AU - Furlanetto, Jenny

AU - Molino, Annamaria

AU - Fiorio, Elena

AU - Chilosi, Marco

AU - Jasani, Bharat

AU - Vergine, Marco

AU - Marcolini, Lisa

AU - Filippini, Dea

AU - Scarpa, Aldo

AU - Martignoni, Guido

AU - Bonetti, Franco

PY - 2013/9

Y1 - 2013/9

N2 - Few data on Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast carcinomas have been reported for screen-detected breast carcinoma. Assessing the impact of a targeted intervention with anti-HER2 inhibitors on costs is required in order to plan for better strategies in screening programs. A total of 54,472 women were screened and 323 cases were found to be invasive cancer. We performed immunophenotypical-fluorescent in situ hybridization (FISH) analysis. Among 153 evaluable breast carcinomas, tumours displayed a 3+ scoring status 3+ in 16 (10%), 2+ in 12 (8%), 1+ in 29 (19%) and 0 in 96 (63%) of cases, respectively. All 3+ HER2+ cases and 2/12 2+ (17%) cases exhibited HER2/neu gene amplification, the remaining cases did not. In contrast to the higher incidence reported at the population level, 20-30% HER2-positive cases for metastatic carcinomas, and only 11% of the screen-detected breast carcinomas displayed HER2/neu gene amplification. Breast cancer detection by screening programs hijacks the skyrocketing cost of the use of targeted therapy in HER2-positive carcinoma.

AB - Few data on Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast carcinomas have been reported for screen-detected breast carcinoma. Assessing the impact of a targeted intervention with anti-HER2 inhibitors on costs is required in order to plan for better strategies in screening programs. A total of 54,472 women were screened and 323 cases were found to be invasive cancer. We performed immunophenotypical-fluorescent in situ hybridization (FISH) analysis. Among 153 evaluable breast carcinomas, tumours displayed a 3+ scoring status 3+ in 16 (10%), 2+ in 12 (8%), 1+ in 29 (19%) and 0 in 96 (63%) of cases, respectively. All 3+ HER2+ cases and 2/12 2+ (17%) cases exhibited HER2/neu gene amplification, the remaining cases did not. In contrast to the higher incidence reported at the population level, 20-30% HER2-positive cases for metastatic carcinomas, and only 11% of the screen-detected breast carcinomas displayed HER2/neu gene amplification. Breast cancer detection by screening programs hijacks the skyrocketing cost of the use of targeted therapy in HER2-positive carcinoma.

KW - Cost-effectiveness

KW - Gene amplification

KW - HER2

KW - Screen-detected breast carcinoma

KW - Screening

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84884991686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884991686&partnerID=8YFLogxK

M3 - Article

C2 - 24023299

AN - SCOPUS:84884991686

VL - 33

SP - 3705

EP - 3710

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 9

ER -